COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu
Trial record 69 of 1228 for:    MYCOPHENOLIC ACID

Mycophenolate Mofetil in Pediatric Steroid Dependent Nephrotic Syndrome

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01895894
Recruitment Status : Completed
First Posted : July 11, 2013
Last Update Posted : July 6, 2017
Chong Kun Dang Pharmaceutical
Information provided by (Responsible Party):
Hee Gyung Kang, Seoul National University Hospital

Brief Summary:

Idiopathic nephrotic syndrome is generally responsive to steroid therapy, but some patients need other immunosuppressants to reduce steroid dependency. The long-term use should be restricted due to adverse effects of cyclosporine, such as hypertension and nephrotoxicity.

Mycophenolate mofetil for steroid-dependent nephrotic syndrome has been reported to have similar efficacy and fewer undesirable effects to other drugs in mainly observational studies. To determine the efficacy of mycophenolate mofetil in the management of steroid-dependent nephrotic syndrome, the investigators designed this prospective randomized controlled study.

Condition or disease Intervention/treatment Phase
Nephrotic Syndrome Drug: Mycophenolate mofetil Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 34 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Prospective, Randomized, Open-label Study Evaluating the Efficacy of Mycophenolate Mofetil in the Prevention of Relapse of Steroid Dependent Nephrotic Syndrome in Children
Actual Study Start Date : September 2013
Actual Primary Completion Date : December 2016
Actual Study Completion Date : December 2016

Arm Intervention/treatment
Experimental: Mycophenolate mofetil Drug: Mycophenolate mofetil
Mycophenolate mofetil 20~30mg/kg/day PO until nephrotic syndrome relapse (max. 1 year)
Other Name: Myrept capsule/tablet

No Intervention: Control

Primary Outcome Measures :
  1. relapse free time [ Time Frame: 1 year ]

Secondary Outcome Measures :
  1. adverse effect [ Time Frame: 1 year ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   2 Years to 24 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Steroid-dependent patients who had been on calcineurin inhibitors continuously for more than 1 year
  • in complete remission

Exclusion Criteria:

  • Hereditary or secondary nephrotic syndrome
  • Estimated glomerular filtration rate (GFR) < 60 mg/min/1.73 m^2
  • Body weight <16 kg
  • leukocytopenia (absolute neutrophil count < 2000/mm^3) or anemia(Hct < 25%)
  • Severe gastrointestinal disease
  • chronic or acute active infection (e.g. hepatitis B,C, herpes, varicella zoster)
  • prior live vaccine inoculation within 6 weeks (from the study enrollment)
  • GOT/GPT elevation or hyperbilirubinemia
  • malignant disease
  • Pregnant or Breast feeding
  • Previous history of mycophenolate mofetil use
  • Participation to other therapeutic trial within recent 3 months
  • Deficiency of the enzyme hypoxanthine-guanine phosphoribosyltransferase

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01895894

Layout table for location information
Korea, Republic of
Seoul National University Children's Hospital
Seoul, Korea, Republic of, 110-740
Sponsors and Collaborators
Seoul National University Hospital
Chong Kun Dang Pharmaceutical
Layout table for investigator information
Principal Investigator: Hee Gyung Aurea Kang, M.D., Ph.D. Seoul National University Hospital
Layout table for additonal information
Responsible Party: Hee Gyung Kang, Associate professor, Seoul National University Hospital Identifier: NCT01895894    
Other Study ID Numbers: MMF2013
First Posted: July 11, 2013    Key Record Dates
Last Update Posted: July 6, 2017
Last Verified: July 2017
Keywords provided by Hee Gyung Kang, Seoul National University Hospital:
Mycophenolate mofetil
Immunosuppressive Agents
Additional relevant MeSH terms:
Layout table for MeSH terms
Mycophenolic Acid
Nephrotic Syndrome
Pathologic Processes
Kidney Diseases
Urologic Diseases
Antibiotics, Antineoplastic
Antineoplastic Agents
Antibiotics, Antitubercular
Antitubercular Agents
Anti-Bacterial Agents
Anti-Infective Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action